About Crescendo Bioscience
Crescendo Bioscience® provides quantitative, objective molecular tests to provide rheumatologists with deeper clinical insights into biology, to help enable more effective management of patients with autoimmune and inflammatory diseases.
Crescendo Bioscience is a molecular diagnostics laboratory concentrating its efforts on rheumatology. The company is currently focused on RA, a debilitating, chronic disease affecting over 1.5 million people in the United States and more than 2 million in Europe. Current tools for assessing the status of RA in individual cases are largely subjective, imprecise, and cumbersome to administer in daily practice. Although there is no known cure for RA, multiple therapies are available, with widely differing levels of effectiveness and significant potential toxicities. Choosing the optimal treatment from among these therapeutic alternatives is a tremendous challenge.
Working with collaborators from leading academic medical institutions, Crescendo Bioscience is building a comprehensive understanding of the biology underlying RA, including the characterization of protein, gene expression, and genetic biomarkers, to provide molecular analysis of the disease to help guide the treatment of individual patients. Crescendo Bioscience plans to establish long-term relationships with clinicians by providing comprehensive diagnostic, prognostic, analytic, therapy selection and monitoring capabilities to help improve outcomes throughout the continuum of care. All testing will be performed at our own specialized, CLIA-certified laboratory.
Crescendo Bioscience is a privately held company and is funded by two of the leading health care venture capital investors: Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.
To learn more about the vision and science behind Crescendo Bioscience, please visit www.crescendobio.com.